The global nucleic acid isolation and purification market is experiencing significant growth, driven by the rising demand for molecular diagnostics, personalized medicine, and biopharmaceutical research. The increasing prevalence of genetic disorders, infectious diseases, and cancer has intensified the need for efficient and accurate nucleic acid extraction techniques, particularly in clinical and research settings. Technological advancements, such as automated systems and magnetic bead-based methods, have streamlined workflows, enhanced yield and purity while reducing processing time. Additionally, the surge in genomic research, propelled by initiatives like the Human Genome Project and advancements in next-generation sequencing (NGS), continues to fuel market expansion.
Global Nucleic Acid Isolation and Purification Market size was valued at USD 7.21 billion in 2024 and is projected to reach USD 15.44 billion by 2032, growing with a CAGR of 10.6% during the forecast period of 2025 to 2032.
To know more, visit https://www.databridgemarketresearch.com/reports/global-nucleic-acid-isolation-purification-market
Below are the Top Nucleic Acid Isolation and Purification Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Merck KGaA
|
Merck KGaA, is a leading global player in the life sciences sector, offering innovative products and solutions for nucleic acid isolation and purification. The company’s extensive portfolio includes high-quality reagents, kits, and consumables designed to deliver accurate, efficient, and reproducible nucleic acid extraction for both research and clinical applications. Merck’s commitment to technological advancement and sustainability, combined with its strong global presence, positions it as a key contributor to the growth of the nucleic acid isolation and purification market.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
Merck KGaA has been actively contributing to the nucleic acid isolation and purification market through various initiatives. Merck partnered with Tecan Group to enhance nucleic acid extraction and purification processes. This collaboration integrates Merck's proprietary chemistry with Tecan's automation capabilities, aiming to improve protocol efficiency, increase throughput, and offer better price performance.
|
|
2.
|
Cytiva
|
Cytiva, a global life sciences leader headquartered in Marlborough, Massachusetts, specializes in technologies that support the development and manufacturing of advanced therapies. The company offers a comprehensive range of nucleic acid isolation and purification products, including automated systems and purification kits, designed to meet the evolving needs of biopharmaceutical research and diagnostics. Cytiva’s focus on innovation and bioprocessing solutions has made it a critical player in driving efficiency and scalability in the nucleic acid purification space.
|
|
North America, Asia-Pacific, and Europe
|
In August 2024, Cytiva introduced several advancements in the nucleic acid isolation and purification market. The company launched a range of Sera-Xtracta™ kits designed for efficient nucleic acid isolation, including the Sera-Xtracta Virus/Pathogen Kit, which facilitates rapid, 30-minute extraction of DNA and RNA from bacteria and viruses, including SARS-CoV-2, ensuring reproducible yields. The Sera-Xtracta High Molecular Weight (HMW) DNA Kit enables high-yield extraction of HMW DNA from various samples such as blood, saliva, cultured cells, and tissues while minimizing RNA contamination. Additionally, the Sera-Xtracta Cell-Free DNA Kit efficiently purifies cell-free DNA (cfDNA) from liquid biopsy samples, including plasma, serum, and urine, selectively isolating small-fragment cfDNA and reducing genomic DNA contamination.
|
|
3.
|
Meridian Bioscienc, Inc. and subsidiaries
|
Meridian Bioscience, Inc., based in Cincinnati, Ohio, is a leading provider of diagnostic testing solutions and life science raw materials. The company’s nucleic acid isolation and purification products are integral to molecular diagnostic applications, including PCR and qPCR assays. Meridian’s commitment to delivering high-quality, user-friendly solutions has helped streamline workflows in clinical laboratories and research institutions, contributing to the growth of the global market.
|
|
North America, Africa, Asia-Pacific, and Europe
|
In March 2021, Meridian launched the Air-Dryable Direct DNA qPCR Blood Mix, a specialized polymerase and advanced buffer formulation optimized for whole blood, serum, and plasma samples. This innovation eliminates the need for DNA purification, allowing for direct amplification from crude blood samples. Additionally, the mix supports a simple oven-drying procedure, facilitating the development of room-temperature stable molecular diagnostic assays.
|
|
4.
|
Bio-Rad Laboratories, Inc.
|
Bio-Rad Laboratories, Inc., headquartered in Hercules, California, is a prominent player in the life sciences and clinical diagnostics markets. The company offers a wide array of nucleic acid isolation and purification products, including automated systems, reagents, and kits designed for high-throughput applications. Bio-Rad’s emphasis on innovation, accuracy, and reliability has positioned it as a trusted partner for researchers and clinicians worldwide, significantly impacting the nucleic acid purification market.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In August 2024, Bio-Rad had launched the VeriCheck ddPCR Empty Full Capsid Kit, designed to enhance the development of safe and effective gene therapies. This high-precision kit enables accurate quantification of viral capsids, improving research and quality control in gene therapy applications.
|
|
5.
|
Agilent Technologies, Inc.
|
Agilent Technologies, Inc., based in Santa Clara, California, is a global leader in life sciences, diagnostics, and applied chemical markets. The company provides advanced nucleic acid isolation and purification solutions that cater to both research and clinical applications. Agilent’s robust portfolio, combined with its focus on precision, automation, and innovation, has made it a key player in advancing nucleic acid technologies, supporting the growth of the global market.
|
|
North America, South America, Asia-Pacific, and Europe
|
In September 2024, Agilent Technologies has completed its acquisition of BIOVECTRA, enhancing its Contract Development and Manufacturing Organization (CDMO) capabilities in biologics and targeted therapeutics. The acquisition strengthens Agilent's portfolio and supports advanced pharmaceutical manufacturing, with expected positive returns by year five.
|
Conclusion
The global nucleic acid isolation and purification market is poised for sustained growth, fueled by the increasing demand for advanced molecular diagnostics, personalized medicine, and biopharmaceutical research. Technological innovations and automation have enhanced the efficiency and accuracy of nucleic acid extraction, broadening its applications across clinical, research, and pharmaceutical sectors. While North America continues to lead due to its strong research infrastructure, the Asia-Pacific region is emerging as a key growth area, driven by rising healthcare investments and biotechnology advancements. Despite challenges such as high equipment costs, the market outlook remains positive, supported by ongoing research initiatives and the expanding role of nucleic acid technologies in modern healthcare.
